TNXP vs. NRSN, EDSA, VINC, FLGC, TRAW, HUGE, PIRS, RDHL, PPBT, and KPRX
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include NeuroSense Therapeutics (NRSN), Edesa Biotech (EDSA), Vincerx Pharma (VINC), Flora Growth (FLGC), Traws Pharma (TRAW), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), RedHill Biopharma (RDHL), Purple Biotech (PPBT), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical preparations" industry.
NeuroSense Therapeutics (NASDAQ:NRSN) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
NeuroSense Therapeutics has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.
In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Tonix Pharmaceuticals and 1 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.43 beat Tonix Pharmaceuticals' score of 0.00 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.
Tonix Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 2,689.05%. Given NeuroSense Therapeutics' higher probable upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than NeuroSense Therapeutics.
NeuroSense Therapeutics has higher earnings, but lower revenue than Tonix Pharmaceuticals. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics' return on equity of -83.03% beat Tonix Pharmaceuticals' return on equity.
Tonix Pharmaceuticals received 337 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. However, 100.00% of users gave NeuroSense Therapeutics an outperform vote while only 63.84% of users gave Tonix Pharmaceuticals an outperform vote.
Summary
Tonix Pharmaceuticals beats NeuroSense Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
